JNJ

NEW YORK STOCK EXCHANGE, INC. · Pharmaceuticals

Johnson & Johnson

S&P 500 Dow Jones Mega-Cap Stocks Blue Chip Stocks Pharmaceutical Stocks Healthcare Stocks Best Dividend Stocks

$221.32

-1.19 (-0.53%)

As of May 9, 2:01 AM ET ·

Financial Highlights (FY 2026)

Revenue

93.68B

Net Income

26.66B

Gross Margin

68.0%

Profit Margin

28.5%

Rev Growth

+5.6%

D/E Ratio

0.59

Revenue & Net Income

Margin Trends

	FY 2026	FY 2025	FY 2024	FY 2023
Gross Margin	68.0%	68.0%	44.0%	44.0%
Operating Margin	34.6%	31.1%	29.5%	29.2%
Profit Margin	28.5%	27.0%	19.9%	21.8%

Income Statement

	FY 2026	FY 2025	FY 2024	FY 2023
Revenue	93.68B	88.71B	81.19B	89.13B
Gross Profit	63.69B	60.31B	35.72B	39.21B
Operating Income	32.40B	27.62B	23.92B	26.00B
Net Income	26.66B	22.72B	16.19B	19.43B
Gross Margin	68.0%	68.0%	44.0%	44.0%
Operating Margin	34.6%	31.1%	29.5%	29.2%
Profit Margin	28.5%	27.0%	19.9%	21.8%
Rev Growth	+5.6%	+5.6%	+12.0%	-8.6%

Balance Sheet

	FY 2026	FY 2025	FY 2024	FY 2023
Total Debt	101.61B	101.61B	181.05B	177.00B
Total Equity	172.86B	172.86B	426.62B	418.52B
D/E Ratio	0.59	0.59	0.42	0.42

Cash Flow

	FY 2026	FY 2025	FY 2024	FY 2023
EBITDA	39.64B	35.66B	32.24B	37.61B
Free Cash Flow	—	—	20.95B	18.85B